GOLIMUAB SIGNIFICANTLY REDUCES THE TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED DATA FROM THREE PHASE 3 STUDIES

Buchanan J1, Emery P2, Keystone E3, Smolen J4, Doyle M5,6, Hiss E7, Rahman MU8, Gathany T9, Han C10, Patrick5,5,11

1Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, USA; 2University of Leeds, Leeds, UK; 3TOKYO CANABINOID PHARMA LIMITED; Mount Sinai Hospital, Toronto, ON, Canada; 4Medical University of Vienna, Vienna, Austria; 5Lentor Research and Development, Inc.; 6Penn Medicine, Philadelphia, PA, USA

OBJECTIVES: To evaluate the effect of golimub (GLM) on time lost from work in patients with rheumatoid arthritis (RA). METHODS: The effect of GLM on time lost from work (days) was prospectively evaluated in 3 multicenter, randomized, double-blind, placebo-controlled studies in patients with RA. Pooled data from patients receiving any injection of study agent (GLM or placebo) with or without methotrexate (MTX) in 3 RA studies (GO-BEFORE, GO-FORWARD, and GO-AFTER) were included. GLM SC injections of 50 or 100 mg were administered q4 weeks. Time lost from work for patients was collected through a questionnaire at baseline and q8 weeks through week 24 and was summarized cumulatively through week 52 in between groups using normal approximation scores. The proportion of patients reporting no time lost from work in the GLM+MTX group was compared with the PBO+MTX group using the chi square test. RESULTS: Through week 24, significant differences in time lost from work were observed between the GLM+MTX group and the PBO+MTX group. At week 24, the PBO+MTX group lost 6.9 vs 19.7 days compared with 5.0 ± 19.4 days for the combined GLM+MTX group. At week 24, the 75th percentile for the combined GLM+MTX group was 1,000 day (range 0-180) compared with 3,000 days (range 0-120) for the PBO+MTX group. A significantly higher proportion of patients in the golimub+MTX group reported no time lost from work compared with the PBO+MTX group (75.3% vs 60.7%; p = 0.002). CONCLUSIONS: GLM+MTX significantly reduced time lost from work for patients with RA compared with PBO+MTX.

THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: ANALYSIS OF THE MEDICAL EXPENSE PANEL SURVEY (MEPS) 2005 AND 2006 DATA

Simons WR1, Chang CY2, Trivedi DN3, Rosenblat LC4

1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA

OBJECTIVES: Previous research reported the prevalence and health care and productivity cost of rheumatoid arthritis (RA) using Medical Expenditure Panel Survey (MEPS) 2004 data; this study replicates the analyses using 2005 and 2006 data. METHODS: MEPS, a comprehensive survey of approximately 35,000 individuals in the US, was used to identify non-institutionalized US persons with RA. Multiple linear and semi-log regressions were applied to estimate total annual health care expenditure and income (yearly wages) associated with RA. Covariates in the expenditure equations included demographics, comorbidities, and overall health status. Semi-log regression results income renders the distribution of income symmetric, Covariates in the income equations included demographics, comorbidities, education, occupation, and health status. RESULTS: A total of 150 and 148 patients with RA were identified in 2005 and 2006 versus 136 in 2004; 75% (2005) and 80% (2006) were women versus 76% (2004), and 53% (2005) and 50% (2006) of RA patients were between the ages 41-64 years versus 56% in 2004. Linear regressions demonstrated that the incremental increase in health care cost associated with RA was $2902 (P = 0.0001) in 2005 and $1882 ($P = 0.003) in 2006, versus $4422 (2004). Semi-log regression explaining wages in 2005 and 2006 had adjusted R2 of 56% and 59%. RA significantly reduced wages by $2207 ($0.9237 log estimate) annually (P < 0.0001) in 2005 and $1,559 ($0.3038 log estimate; P = 0.05) in 2006; wages of RA patients in 2004 were reduced by $3526 ($-1.088 log estimate). CONCLUSIONS: The economic impact of RA is substantial to both income loss and health care costs. Replication and validation of outcomes research is important to establish the precision of statistical associations as well as changes across time. Further study will explore whether changes in the care of patients with RA affect changes in outcomes over time.
were calculated for each treatment strategy and severity level. Four types of items were surveyed: treatment strategy for VCF (A=Hospitalization only, B=Hospitalization to outpatient, C=outpatient visit only, D=operation, E=follow-up only, F=other), treatment period of each VCF therapy (length of stay and outpatient visit), examination items (physical, laboratory test) and therapeutic regimens (use of cast or on hard/soft corset, rehabilitation, nerve block, medication). Severity of VCF was classified into three levels: status1 (lumbar back pain/LD; impairment; neurological symptoms/), status2 (x+y+z), status3 (x+y+z). RESULTS: The questionnaire was administered to 83 patients, and 65 responses (response rate 82%) were received. Of these, 65 responses were available for estimation. When considering the proportions of treatment strategies (A to C), the expected medical costs for each status were: status1; US$1637, status2; US$4485 and status3; US$7962 (US$ = 92JPY). The expected costs of CMM for a patient with osteoporotic VCF in Japan was estimated at US$4,032, and the total annual costs of CMM for VCF on a national scale were estimated to be US$1,18 billion. CONCLUSIONS: Japan being an aging society, the burden of illness for VCF is a significant issue. Further standardization and customization of treatment modalities are expected for optimal allocation of medical resources.

PM534
AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABACTEPT IN THE TREATMENT OF MODERATE TO SEvere RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA
Jung J, Mistry B
HealthCare-LA Riche, Mississauga, ON, Canada
OBJECTIVES: Rituximab (RTX) and abactept (ABAT) are novel therapies to treat moderate to severe Rheumatoid Arthritis (RA). This analysis was conducted to evaluate the cost-effectiveness of these two therapies in patients with active RA who have had an inadequate response to anti-tumour necrosis factor (TNF) inhibitor treatment from the Ontario Ministry of Health perspective. METHODS: A cost-utility model was used to evaluate the direct costs and outcomes of a standard Canadian treatment sequence in the absence and presence of either RTX + methotrexate (MTX) or ABAT + MTX after failure of one anti-TNF. The model simulated 10,000 RA patients over a lifetime. RTX and ABAT were evaluated against the following standard Canadian treatment sequence after failure of one anti-TNF (etanercept): adalimumab + MTX, infliximab + MTX, leflunomide, gold, cyclosporine and palliative care. Baseline characteristics from REFLEX (Randomised Evaluation of Long-term Efficacy of Rituximab in RA) clinical trial were: mean age, 52.2 years; mean HAQ score, 1.88. ACR response rates from RCTs were placebo-adjusted to minimize bias from cross-trial comparisons. All relevant direct costs were included in the model including drug costs, administration and monitoring, and adverse events. Observational data were used to estimate long-term HAQ progression and average time on treatment for patients responding to therapy. Costs and benefits were discounted at 5% per annum. RESULTS: The introduction of RTX following failure of one biologic resulted in a gain of 0.445 QALYs at an additional total cost of $3710 resulting in an ICER of $8380/QALY. The introduction of ABAT following failure of one biologic resulted in a gain of 0.387 QALYs at an additional total cost of $18,588 resulting in an ICER of $48,800/QALY. CONCLUSIONS: Rituximab is economically attractive from a Canadian payer perspective and is a cost-effective treatment option over abactept when compared in the studied population.

MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies

PM535
IMPACT OF A SUPPORT PROGRAM ON THE TREATMENT COMPLIANCE IN OSTEOPOROSIS PATIENTS
Guizzo MH, Muramú AM
Prédio Reche, Quercus e Farmacêuticos 1A, São Paulo, São Paulo, Brazil, *Universidade Federal de São Paulo, São Paulo, SP, Brazil
OBJECTIVES: To assess the extension in which the participation of a patient in a support program contributes with increased osteoporosis treatment compliance. Trials demonstrated that the compliance rates to oral bisphosphonates therapy present a significant drop along the first year of treatment and continue declining year after year. The objective of a support program is to provide patient’s support providing information about the disease, to interchange experiences with other patients, provide high calcium content nutrition tips and proper physical activities. METHODS: Quantitative study conducted through personal and individual interviews using a structured questionnaire. Two hundred and twenty interviews were conducted with female patients that concluded the bisphosphate treatment, divided in two groups: one hundred-two registered and one hundred and eighteen non-registered into a support program. RESULTS: The average treatment period with bisphosphate between the patients registered in the program is of 11 months vs. 4 months for non-registered patients. The main causes of impact on the continuous use of bisphosphonate of the patients non-registered in a support program include the treatment side effects (28% vs. 7%), the lack of follow-up (14% vs. 14%), from the total of patients interrupting the intake of bisphosphonate due to side effects the largest number are due to gastric problems. However, the patients registered in a support program reach the treatment final (34% vs. 15%; p < 0.01). CONCLUSIONS: The patients registered in a support program present the tendency to follow the prescription and remain for a longer time period in the therapy.

PM537
QUALITY OF LIFE AND COMPLIANCE IN GIRLS WITH ADOLESCENT IDIOPATHIC SCOLIOSIS
Revert L, Lodsenga
Department of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa
OBJECTIVES: The Brace Questionnaire (BrQ) is a recently-developed, condition-specific tool used to measure quality of life (QoL) in subjects with spinal bracing. While corrective bracing for adolescent idiopathic scoliosis (AIS) has more favourable outcomes when patients are compliant, one must appreciate that bracing itself may be a stressful and traumatic experience, and compliance and a bracing protocol is likely to be dependent upon patients’ physical, emotional and social well-being. Using the BrQ we sought to explore relationships between QoL and compliance with treatment. METHODS: The BrQ was administered to 31 AIS patients after a minimum of 1 year of wearing a brace for 1 year. Subjects were 13–16 year-old girls with significant deformity (Cobb angles 25–40 degrees). Participants were divided into two groups according to their level of compliance with the bracing protocol. BrQ sub- and total scores were compared between the two groups using the t-test for comparison of means. RESULTS: Twenty patients were classified as compliant and 11 as non-compliant. Mean total BrQ scores (expressed as a percentage) were 83.7 for the compliant group and 64.4 for the non-compliant group (p < 0.001). The compliant group scored significantly higher in six of the eight domains that make up the BrQ. Compliant patients had greater vitality and self esteem, and function better in those domains covering physical, emotional and social roles. CONCLUSIONS: Poor QoL adversely affects compliance in AIS patients requiring a brace. Non-compliant patients lack vitality and self esteem, and function poorly in the physical, emotional and social domains. Quality of life for adolescents with moderate scoliosis may correlate more with psychosocial coping mechanisms than to physical deformity and its consequences. It is important for remedial programmes to consider personal, peer and family issues as part of improving QoL, promoting compliance and correcting deformity.

PM538
PATIENTS SUCCESS CRITERIA AND EXPECTATIONS IN FALLS REHABILITATION
Price J
Department of Veterans Affairs, Gainesville, FL, USA
OBJECTIVES: Performance-based instruments commonly used in clinical settings often do not capture important aspects of the patient’s health experience. Therefore, the primary aim of this study was to use a patient reported outcomes (PRO) questionnaire to investigate patient’s success criteria and expectations when receiving rehabilitation services related to falls. METHODS: A group of patients (N = 50, age = 55+) receiving physical therapy services were enrolled. Inclusion criteria consisted of: community-dwelling with a history of falling, ability to walk 20 ft. and Mini-Mental State Exam score >24. The Patient’s Perspective Outcome Questionnaire (PPOQ) was administered at the initial physical therapy evaluation. PPOQ assesses current levels, success criteria and expected levels for a number of health domains including: mobility, self-care, interactions with people, community/social life, energy/drive, mental function, emotional distress, sensory function, and pain. A 100 point scale measures levels of interference across domains (0 – not affected and 100 – most affected). RESULTS: Participants reported highest scores in the energy/drive (53), mobility (47), and pain (44) domains. Interactions with people (21) and community/social life (31) received the lowest scores, suggesting that domains with a strong social component were not as affected as domains with a strong physical component. Participants required significant improvement to consider their treatment successful. The mobility and energy/drive domains required significantly larger reductions than the community/social life, and interactions with people domains (p < 0.006). Across all domains, participant’s expectation was the treatment would not meet their success criteria, indicating that residual levels of impairment were expected after treatment. CONCLUSIONS: The results of this study point out that a number of health domains are significantly affected in this population. These patient have treatment expectations that exceed the mobility problems for which they were treated. In exploring meaningful change, the patient’s expectations and success criteria must be considered.

PM539
IMPAIRMENTS IN QUALITY OF LIFE, DAILY FUNCTION, AND WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES
Liang Y, Niam A, McGarva RN, Bailey W, Freedman D, Waggon V, Pach CT
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, *Centocor Ortho Biotech Services, LLC, Horsham, NJ, USA, Center for Health Sciences International, Princeton, NJ
OBJECTIVES: To assess symptoms, functionality, quality of life (QoL), and work/ productivity loss in Rheumatoid Arthritis (RA) patients treated with subcutaneous (SC) biologics. METHODS: Patient-reported data from the 2007 Rheumatoid Arthritis Patient Study were analyzed. Symptoms were measured by morning stiffness, fatigue, and pain scores defined on a scale from 0 (no symptom) to 10 (severe)